Pro-angiogenic cytokines as cardiovascular therapeutics: Assessing the potential

BioDrugs

Volumn 22, Issue 4, 2008, Pages 209-222

  Atluri, Pavan ^a   Woo, Y Joseph ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Angiogenesis inducing agents, general; Cardiovascular disorders; Coronary artery disease; Cytokines, general; Fibroblast growth factor, general; Hepatocyte growth factor, general; Peripheral arterial disorders; Research and development

Indexed keywords

ADENOVIRUS VECTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLACENTAL GROWTH FACTOR; PLASMID VECTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; VASCULOTROPIN; VASCULOTROPIN 165;

ANGIOGENESIS; ANGIOGENIC GENE THERAPY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR GENE THERAPY; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; ENDOTHELIUM CELL; GENERAL CONDITION IMPROVEMENT; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPOTENSION; MEMBRANOUS GLOMERULONEPHRITIS; MUSCLE ISCHEMIA; NONHUMAN; NOTE; PERFUSION; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION; SUSTAINED DRUG RELEASE; TISSUE ENGINEERING; UPREGULATION;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CARDIOVASCULAR DISEASES; CHEMOKINE CXCL12; CYTOKINES; FIBROBLAST GROWTH FACTORS; HEPATOCYTE GROWTH FACTOR; HUMANS; MYOCARDIAL REVASCULARIZATION; PREGNANCY PROTEINS; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 47049122030     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200822040-00001     Document Type: Note

References (165)

1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics, 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007 Feb 6; 115 (5): e69-171
2. Boodhwani M, Sodha NR, Laham RJ, et al. The future of therapeutic myocardial angiogenesis. Shock 2006 Oct; 26 (4): 332-41
3. Szmitko PE, Fedak PW, Weisel RD, et al. Endothelial progenitor cells: new hope for a broken heart. Circulation 2003 Jun 24; 107 (24): 3093-100
4. Assmus B, Schachinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002 Dec 10; 106 (24): 3009-17
5. Britten MB, Abolmaali ND, Assmus B, et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation 2003 Nov 4; 108 (18): 2212-8
6. Erbs S, Linke A, Adams V, et al. Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebo-controlled study. Circ Res 2005 Oct 14; 97 (8): 756-62
7. Perin EC, Dohmann HF, Borojevic R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003 May 13; 107 (18): 2294-302
8. Shi Q, Rafii S, Wu MH, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998 Jul 15; 92 (2): 362-7
9. Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001 Jun 12; 103 (23): 2776-9
10. Gill M, Dias S, Hattori K, et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res 2001 Feb 2; 88 (2): 167-74
11. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999 Apr; 5 (4): 434-8
12. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000 Feb 1; 95 (3): 952-8
13. Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002 Jun 25; 105 (25): 3017-24
14. Toyota E, Warltier DC, Brock T, et al. Vascular endothelial growth factor is required for coronary collateral growth in the rat. Circulation 2005 Oct 4; 112 (14): 2108-13
15. Ray PS, Estrada-Hernandez T, Sasaki H, et al. Early effects of hypoxia/reoxygenation on VEGF, ang-1, ang-2 and their receptors in the rat myocardium: implications for myocardial angiogenesis. Mol Cell Biochem 2000 Oct; 213 (1-2): 145-53
16. Ray PS, Sasaki H, Estrada-Hernandez T, et al. Effects of hypoxia/reoxygenation on angiogenic factors and their tyrosine kinase receptors in the rat myocardium. Antioxid Redox Signal 2001 Feb; 3 (1): 89-102
17. Maulik N. Angiogenic signal during cardiac repair. Mol Cell Biochem 2004 Sep; 264 (1-2): 13-23
18. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998 Mar 31; 97 (12): 1114-23
19. Yamaguchi J, Kusano KF, Masuo O, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003 Mar 11; 107 (9): 1322-8
20. Jayasankar V, Woo YJ, Bish LT, et al. Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure. Circulation 2003 Sep 9; 108 Suppl. 1: II230-6
21. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004 Aug; 10 (8): 858-64
22. Liu YJ, Lu SH, Xu B, et al. Hemangiopoietin, a novel human growth factor for the primitive cells of both hematopoietic and endothelial cell lineages. Blood 2004 Jun 15; 103 (12): 4449-56
23. Burger PE, Coetzee S, McKeehan WL, et al. Fibroblast growth factor receptor-1 is expressed by endothelial progenitor cells. Blood 2002 Nov 15; 100 (10): 3527-35
24. Kashiwakura I, Takahashi TA. Basic fibroblast growth factor-stimulated ex vivo expansion of haematopoietic progenitor cells from human placental and umbilical cord blood. Br J Haematol 2003 Aug; 122 (3): 479-88
25. Tomanek RJ, Sandra A, Zheng W, et al. Vascular endothelial growth factor and basic fibroblast growth factor differentially modulate early postnatal coronary angiogenesis. Circ Res 2001 Jun 8; 88 (11): 1135-41
26. Detillieux KA, Sheikh F, Kardami E, et al. Biological activities of fibroblast growth factor-2 in the adult myocardium. Cardiovasc Res 2003 Jan; 57 (1): 8-19
27. Sugi Y, Lough J. Activin-A and FGF-2 mimic the inductive effects of anterior endoderm on terminal cardiac myogenesis in vitro. Dev Biol 1995 Apr; 168 (2): 567-74
28. Solloway MJ, Harvey RP. Molecular pathways in myocardial development: a stem cell perspective. Cardiovasc Res 2003 May 1; 58 (2): 264-77
29. Rosenblatt-Velin N, Lepore MG, Cartoni C, et al. FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes. J Clin Invest 2005 Jul; 115 (7): 1724-33
30. Fujita M, Ikemoto M, Kishishita M, et al. Elevated basic fibroblast growth factor in pericardial fluid of patients with unstable angina. Circulation 1996 Aug 15; 94 (4): 610-3
31. Scarborough JE, Smith ML, Domkowski PW, et al. Basic fibroblast growth factor is upregulated in hibernating myocardium. J Surgical Res 2002 Sep; 107 (1): 119-23
32. Fernandez B, Buehler A, Wolfram S, et al. Transgenic myocardial overexpression of fibroblast growth factor-1 increases coronary artery density and branching. Circ Res 2000 Aug 4; 87 (3): 207-13
33. Battler A, Scheinowitz M, Bor A, et al. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J Am Coll Cardiol 1993 Dec; 22 (7): 2001-6
34. Yanagisawa-Miwa A, Uchida Y, Nakamura F, et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992 Sep 4; 257 (5075): 1401-3
35. Laham RJ, Rezaee M, Post M, et al. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia. J Pharmacol Exp Ther 2000 Feb; 292 (2): 795-802
36. Harada K, Grossman W, Friedman M, et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest 1994 Aug; 94 (2): 623-30
37. Sato K, Laham RJ, Pearlman JD, et al. Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia. Ann Thoracic Surg 2000 Dec; 70 (6): 2113-8
38. Liu Y, Sun L, Huan Y, et al. Effects of basic fibroblast growth factor microspheres on angiogenesis in ischemic myocardium and cardiac function: analysis with dobutamine cardiovascular magnetic resonance tagging. Eur J Cardiothorac Surg 2006 Jul; 30 (1): 103-7
39. Giordano FJ, Ping P, McKirnan MD, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996 May; 2 (5): 534-9
40. Sakakibara Y, Tambara K, Sakaguchi G, et al. Toward surgical angiogenesis using slow-released basic fibroblast growth factor. Eur J Cardiothorac Surg 2003 Jul; 24 (1): 105-11; discussion 112
41. Hughes GC, Biswas SS, Yin B, et al. Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF. Ann Thoracic Surg 2004 Mar; 77 (3): 812-8
42. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002 Mar 19; 105 (11): 1291-7
43. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002 Feb 19; 105 (7): 788-93
44. Laham RJ, Sellke FW, Edelman ER, et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999 Nov 2; 100 (18): 1865-71
45. Comerota AJ, Throm RC, Miller KA, et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 2002 May; 35 (5): 930-6
46. Grines CL, Watkins MW, Mahmarian JJ, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003 Oct 15; 42 (8): 1339-47
47. Ruel M, Laham RJ, Parker JA, et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 2002 Jul; 124 (1): 28-34
48. Nikol S, Baumgartner I, Van Belle E, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia: late breaking clinical trial. 55th Annual Scientific Session of the American College of Cardiology; 2006 Mar 11-14; Atlanta (GA)
49. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999 Aug 3; 100 (5): 468-74
50. Fuchs S, Dib N, Cohen BM, et al. A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease. Catheter Cardiovasc Interv 2006 Sep; 68 (3): 372-8
51. Symes JF, Losordo DW, Vale PR, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thoracic Surg 1999 Sep; 68 (3): 830-6; discussion 836-7
52. Makinen K, Manninen H, Hedman M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002 Jul; 6 (1): 127-33
53. Rajagopalan S, Mohler III ER, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003 Oct 21; 108 (16): 1933-8
54. Kusumanto YH, van Weel V, Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 2006 Jun; 17 (6): 683-91
55. Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF (121) (AdVEGF121) versus maximum medical treatment. Gene Ther 2006 Nov; 13 (21): 1503-11
56. Ripa RS, Wang Y, Jorgensen E, et al. Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J 2006 Aug; 27 (15): 1785-92
57. Kastrup J, Jorgensen E, Ruck A, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris: a randomized double-blind placebo-controlled study. The Euroinject One trial. J Am Coll Cardiol 2005 Apr 5; 45 (7): 982-8
58. Hedman M, Hartikainen J, Syvanne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003 Jun 3; 107 (21): 2677-83
59. Aoki M. Clinical trial of human gene therapy using hepatocyte growth factor gene transfer. 69th Annual Scientific Meeting of the Japanese Circulation Society; 2005 Mar 19-21; Yokohama
60. Post MJ, Laham R, Sellke FW, et al. Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc Res 2001 Feb 16; 49 (3): 522-31
61. Ruel M, Wu GF, Khan TA, et al. Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a swine endothelial dysfunction model. Circulation 2003 Sep 9; 108 Suppl. 1: II335-40
62. Voisine P, Li J, Bianchi C, et al. Effects of L-arginine on fibroblast growth factor 2-induced angiogenesis in a model of endothelial dysfunction. Circulation 2005 Aug 30; 112 (9 Suppl.): I202-7
63. Takeshita S, Isshiki T, Sato T. Increased expression of direct gene transfer into skeletal muscles observed after acute ischemic injury in rats. Lab Invest 1996 Jun; 74 (6): 1061-5
64. Toyota E, Matsunaga T, Chilian WM. Myocardial angiogenesis. Mol Cell Biochem 2004 Sep; 264 (1-2): 35-44
65. Flamme I, Breier G, Risau W. Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (flk-1) are expressed during vasculogenesis and vascular differentiation in the quail embryo. Dev Biol 1995 Jun; 169 (2): 699-712
66. Kalka C, Tehrani H, Laudenberg B, et al. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. Ann Thoracic Surg 2000 Sep; 70 (3): 829-34
67. Hattori K, Dias S, Heissig B, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001 May 7; 193 (9): 1005-14
68. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999 Jul 15; 18 (14): 3964-72
69. Kalka C, Masuda H, Takahashi T, et al. Vascular endothelial growth factor (165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000 Jun 23; 86 (12): 1198-202
70. Brogi E, Schatteman G, Wu T, et al. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest 1996 Jan 15; 97 (2): 469-76
71. Lee KW, Lip GY, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 2004 Oct 19; 110 (16): 2355-60
72. Vera Janavel G, Crottogini A, Cabeza Meckert P, et al. Plasmid-mediated VEGF gene transfer induces cardiomyogenesis and reduces myocardial infarct size in sheep. Gene Ther 2006 Aug; 13 (15): 1133-42
73. Hao X, Mansson-Broberg A, Grinnemo KH, et al. Myocardial angiogenesis after plasmid or adenoviral VEGF-A (165) gene transfer in rat myocardial infarction model. Cardiovasc Res 2007 Feb 1; 73 (3): 481-7
74. Ferrarini M, Arsic N, Recchia FA, et al. Adeno-associated virus-mediated transduction of VEGF165 improves cardiac tissue viability and functional recovery after permanent coronary occlusion in conscious dogs. Circ Res 2006 Apr 14; 98 (7): 954-61
75. Kim C, Li RK, Li G, et al. Effects of cell-based angiogenic gene therapy at 6 months: persistent angiogenesis and absence of oncogenicity. Ann Thoracic Surg 2007 Feb; 83 (2): 640-6
76. Zhang H, Zhu SJ, Wang W, et al. Transplantation of microencapsulated genetically modified xenogeneic cells augments angiogenesis and improves heart function. Gene Ther 2008; 15 (1): 40-8
77. Lopez JJ, Laham RJ, Stamler A, et al. VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc Res 1998 Nov; 40 (2): 272-81
78. van Weel V, Deckers MM, Grimbergen JM, et al. Vascular endothelial growth factor overexpression in ischemic skeletal muscle enhances myoglobin expression in vivo. Circ Res 2004 Jul 9; 95 (1): 58-66
79. Dai Q, Huang J, Klitzman B, et al. Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. Circulation 2004 Oct 19; 110 (16): 2467-75
80. Gyongyosi M, Khorsand A, Zamini S, et al. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation 2005; 112 (9 Suppl.): I157-65
81. Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001 Apr; 7 (4): 425-9
82. Moulton KS, Heller E, Konerding MA, et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999 Apr 6; 99 (13): 1726-32
83. Lopez JJ, Laham RJ, Carrozza JP, et al. Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. Am J Physiol 1997 Sep; 273 (3 Pt 2): H1317-23
84. Autiero M, Luttun A, Tjwa M, et al. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003 Jul; 1 (7): 1356-70
85. Iyer S, Leonidas DD, Swaminathan GJ, et al. The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 A resolution. J Biol Chem 2001 Apr 13; 276 (15): 12153-61
86. Iwama H, Uemura S, Naya N, et al. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction. J Am Coll Cardiol 2006 Apr 18; 47 (8): 1559-67
87. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002 Aug; 8 (8): 831-40
88. Nagura S, Katoh R, Miyagi E, et al. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density. Hum Pathol 2001 Jan; 32 (1): 10-7
89. Herold-Mende C, Steiner HH, Andl T, et al. Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab Invest 1999 Dec; 79 (12): 1573-82
90. Roy H, Bhardwaj S, Babu M, et al. Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A. Hum Gene Ther 2005 Dec; 16 (12): 1422-8
91. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001 May; 7 (5): 575-83
92. Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003 Jul; 9 (7): 936-43
93. Pipp F, Heil M, Issbrucker K, et al. VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ Res 2003 Mar 7; 92 (4): 378-85
94. Hattori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 2002 Aug; 8 (8): 841-9
95. Li B, Sharpe EE, Maupin AB, et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 2006 Jul; 20 (9): 1495-7
96. Kolakowski Jr S, Berry MF, Atluri P, et al. Placental growth factor provides a novel local angiogenic therapy for ischemic cardiomyopathy. J Card Surg 2006 Nov-Dec; 21 (6): 559-64
97. Ono K, Matsumori A, Shioi T, et al. Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 1997 Jun 3; 95 (11): 2552-8
98. Ueda H, Nakamura T, Matsumoto K, et al. A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats. Cardiovasc Res 2001 Jul; 51 (1): 41-50
99. Ueda H, Sawa Y, Matsumoto K, et al. Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart. Ann Thoracic Surg 1999 Jun; 67 (6): 1726-31
100. Nakamura T, Mizuno S, Matsumoto K, et al. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 2000 Dec; 106 (12): 1511-9
101. Jin H, Yang R, Li W, et al. Early treatment with hepatocyte growth factor improves cardiac function in experimental heart failure induced by myocardial infarction. J Pharmacol Exp Ther 2003 Feb; 304 (2): 654-60
102. Jin H, Wyss JM, Yang R, et al. The therapeutic potential of hepatocyte growth factor for myocardial infarction and heart failure. Curr Pharm Des 2004; 10 (20): 2525-33
103. Sato T, Tani Y, Murao S, et al. Focal enhancement of expression of c-Met/hepatocyte growth factor receptor in the myocardium in human myocardial infarction. Cardiovasc Pathol 2001 Sep-Oct; 10 (5): 235-40
104. Jayasankar V, Woo YJ, Pirolli TJ, et al. Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure. J Card Surg 2005 Jan-Feb; 20 (1): 93-101
105. Azuma J, Taniyama Y, Takeya Y, et al. Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy. Gene Ther 2006 Aug; 13 (16): 1206-13
106. Ahmet I, Sawa Y, Iwata K, et al. Gene transfection of hepatocyte growth factor attenuates cardiac remodeling in the canine heart: a novel gene therapy for cardiomyopathy. J Thorac Cardiovasc Surg 2002 Nov; 124 (5): 957-63
107. Funatsu T, Sawa Y, Ohtake S, et al. Therapeutic angiogenesis in the ischemic canine heart induced by myocardial injection of naked complementary DNA plasmid encoding hepatocyte growth factor. J Thorac Cardiovasc Surg 2002 Dec; 124 (6): 1099-105
108. Miyagawa S, Sawa Y, Taketani S, et al. Myocardial regeneration therapy for heart failure: hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation 2002 May 28; 105 (21): 2556-61
109. Duan HF, Wu CT, Wu DL, et al. Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Mol Ther 2003 Sep; 8 (3): 467-74
110. Taniyama Y, Morishita R, Aoki M, et al. Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension 2002 Jul; 40 (1): 47-53
111. Yasuda S, Goto Y, Baba T, et al. Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function. J Am Coll Cardiol 2000 Jul; 36 (1): 115-21
112. Sherman JA, Hall A, Malenka DJ, et al. Humoral and cellular factors responsible for coronary collateral formation. Am J Cardiol 2006 Nov 1; 98 (9): 1194-7
113. Wang W, Yang ZJ, Ma DC, et al. Induction of collateral artery growth and improvement of post-infarct heart function by hepatocyte growth factor gene transfer. Acta Pharmacol Sin 2006 May; 27 (5): 555-60
114. Kucia M, Dawn B, Hunt G, et al. Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. Circ Res 2004 Dec 10; 95 (12): 1191-9
115. Ryugo M, Sawa Y, Ono M, et al. Myocardial protective effect of human recombinant hepatocyte growth factor for prolonged heart graft preservation in rats. Transplantation 2004 Oct 27; 78 (8): 1153-8
116. Wang Y, Ahmad N, Wani MA, et al. Hepatocyte growth factor prevents ventricular remodeling and dysfunction in mice via Akt pathway and angiogenesis. J Mol Cell Cardiol 2004 Nov; 37 (5): 1041-52
117. Nakamura T, Matsumoto K, Mizuno S, et al. Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts. Am J Physiol Heart Circ Physiol 2005 May; 288 (5): H2131-9
118. Shirakawa Y, Sawa Y, Takewa Y, et al. Gene transfection with human hepatocyte growth factor complementary DNA plasmids attenuates cardiac remodeling after acute myocardial infarction in goat hearts implanted with ventricular assist devices. J Thorac Cardiovasc Surg 2005 Sep; 130 (3): 624-32
119. AnGes. Study of hepatocyte growth factor (HGF) via plasmid vector to improve perfusion in CLI patients with peripheral ischemic ulcers [clinicaltrials.gov identifier: NCT00189540; online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2008 Jun 24]
120. Bleul CC, Fuhlbrigge RC, Casasnovas JM, et al. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996 Sep 1; 184 (3): 1101-9
121. Elmadbouh I, Haider H, Jiang S, et al. Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium. J Mol Cell Cardiol 2007 Apr; 42 (4): 792-803
122. Mirshahi F, Pourtau J, Li H, et al. SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models. Thromb Res 2000 Sep 15; 99 (6): 587-94
123. Heeschen C, Lehmann R, Honold J, et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 2004 Apr 6; 109 (13): 1615-22
124. Mohle R, Bautz F, Rafii S, et al. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 1998 Jun 15; 91 (12): 4523-30
125. Kanda S, Mochizuki Y, Kanetake H. Stromal cell-derived factor-1alpha induces tube-like structure formation of endothelial cells through phosphoinositide 3-kinase. J Biol Chem 2003 Jan 3; 278 (1): 257-62
126. Kim CH, Broxmeyer HE. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment. Blood 1998 Jan 1; 91 (1): 100-10
127. Aiuti A, Webb IJ, Bleul C, et al. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997 Jan 6; 185 (1): 111-20
128. Lataillade JJ, Clay D, Dupuy C, et al. Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor survival. Blood 2000 Feb 1; 95 (3): 756-68
129. Salvucci O, Yao L, Villalba S, et al. Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood 2002 Apr 15; 99 (8): 2703-11
130. McGrath KE, Koniski AD, Maltby KM, et al. Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4. Dev Biol 1999 Sep 15; 213 (2): 442-56
131. Jo DY, Rafii S, Hamada T, et al. Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1. J Clin Invest 2000 Jan; 105 (1): 101-11
132. Pillarisetti K, Gupta SK. Cloning and relative expression analysis of rat stromal cell derived factor-1 (SDF-1)1: SDF-1 alpha mRNA is selectively induced in rat model of myocardial infarction. Inflammation 2001 Oct; 25 (5): 293-300
133. Wojakowski W, Tendera M, Michalowska A, et al. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 2004 Nov 16; 110 (20): 3213-20
134. Wojakowski W, Tendera M, Zebzda A, et al. Mobilization of CD34(+), CD117(+), CXCR4(+), c-met(+) stem cells is correlated with left ventricular ejection fraction and plasma NT-proBNP levels in patients with acute myocardial infarction. Eur Heart J 2006 Feb; 27 (3): 283-9
135. Damas JK, Waehre T, Yndestad A, et al. Stromal cell-derived factor-1alpha in unstable angina: potential antiinflammatory and matrix-stabilizing effects. Circulation 2002 Jul 2; 106 (1): 36-42
136. Hiasa K, Ishibashi M, Ohtani K, et al. Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation 2004 May 25; 109 (20): 2454-61
137. Woo YJ, Grand TJ, Berry MF, et al. Stromal cell-derived factor and granulocyte-monocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy. J Thorac Cardiovasc Surg 2005 Aug; 130 (2): 321-9
138. Atluri P, Liao GP, Panlilio CM, et al. Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy. Ann Thoracic Surg 2006 May; 81 (5): 1728-36
139. Kohmoto T, Argenziano M, Yamamoto N, et al. Assessment of transmyocardial perfusion in alligator hearts. Circulation 1997 Mar 18; 95 (6): 1585-91
140. Kohmoto T, Fisher PE, Gu A, et al. Does blood flow through holmium: YAG transmyocardial laser channels? Ann Thoracic Surg 1996 Mar; 61 (3): 861-8
141. Wadia Y, Khaki A, Kajitani M, et al. Effects of transmyocardial laser revascularization by using a prototype pulsed CO2 laser on contractility and perfusion of chronically ischemic myocardium in a porcine model. Asaio J 2000 Nov-Dec; 46 (6): 786-91
142. Kohmoto T, Fisher PE, Gu A, et al. Physiology, histology, and 2-week morphology of acute transmyocardial channels made with a CO2 laser. Ann Thoracic Surg 1997 May; 63 (5): 1275-83
143. Allen KB, Dowling RD, Schuch DR, et al. Adjunctive transmyocardial revascularization: five-year follow-up of a prospective, randomized trial. Ann Thoracic Surg 2004 Aug; 78 (2): 458-65; discussion 458-65
144. Allen KB, Dowling RD, Fudge TL, et al. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. N Engl J Med 1999 Sep 30; 341 (14): 1029-36
145. Frazier OH, March RJ, Horvath KA. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. N Engl J Med 1999 Sep 30; 341 (14): 1021-8
146. Burkhoff D, Schmidt S, Schulman SP, et al. Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomised trial. ATLANTIC Investigators. Angina Treatments-Lasers and Normal Therapies in Comparison. Lancet 1999 Sep 11; 354 (9182): 885-90
147. Horvath KA, Aranki SF, Cohn LH, et al. Sustained angina relief 5 years after transmyocardial laser revascularization with a CO (2) laser. Circulation 2001 Sep 18; 104 (12 Suppl. 1): I81-4
148. Horvath KA, Chiu E, Maun DC, et al. Up-regulation of vascular endothelial growth factor mRNA and angiogenesis after transmyocardial laser revascularization. Ann Thoracic Surg 1999 Sep; 68 (3): 825-9
149. Pelletier MP, Giaid A, Sivaraman S, et al. Angiogenesis and growth factor expression in a model of transmyocardial revascularization. Ann Thoracic Surg 1998 Jul; 66 (1): 12-8
150. Atluri P, Panlilio CM, Liao CM, et al. Transmyocardial revascularization to enhance myocardial vasculogenesis and hemodynamic function. J Thorac Cardiovasc Surg 2008; 135 (2): 283-91
151. Tong Q, Zheng L, Lin L, et al. Participation of the PI-3K/Akt-NF-kappa B signaling pathways in hypoxia-induced mitogenic factor-stimulated Flk-1 expression in endothelial cells. Respir Res 2006; 7: 101
152. Sasaki H, Ray PS, Zhu L, et al. Oxidative stress due to hypoxia/reoxygenation induces angiogenic factor VEGF in adult rat myocardium: possible role of NFkappaB. Toxicology 2000 Nov 30; 155 (1-3): 27-35
153. Sasaki H, Ray PS, Zhu L, et al. Hypoxia/reoxygenation promotes myocardial angiogenesis via an NF kappa B-dependent mechanism in a rat model of chronic myocardial infarction. J Mol Cell Cardiol 2001 Feb; 33 (2): 283-94
154. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006 May 25; 441 (7092): 431-6
155. Takahashi K, Ito Y, Morikawa M, et al. Adenoviral-delivered angiopoietin-1 reduces the infarction and attenuates the progression of cardiac dysfunction in the rat model of acute myocardial infarction. Mol Ther 2003 Oct; 8 (4): 584-92
156. Siddiqui AJ, Blomberg P, Wardell E, et al. Combination of angiopoietin-1 and vascular endothelial growth factor gene therapy enhances arteriogenesis in the ischemic myocardium. Biochem Biophys Res Commun 2003 Oct 24; 310 (3): 1002-9
157. Yeh ET, Zhang S, Wu HD, et al. Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation 2003 Oct 28; 108 (17): 2070-3
158. Kinnaird T, Stabile E, Burnett MS, et al. Bone-marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences. Circ Res 2004 Aug 20; 95 (4): 354-63
159. Sze SK, de Kleijn DP, Lai RC, et al. Elucidating the secretion proteome of human embryonic stem cell-derived mesenchymal stem cells. Mol Cell Proteomics 2007 Oct; 6 (10): 1680-9
160. Mansbridge JN, Liu K, Pinney RE, et al. Growth factors secreted by fibroblasts: role in healing diabetic foot ulcers. Diabetes Obes Metab 1999 Sep; 1 (5): 265-79
161. Pinney E, Liu K, Sheeman B, et al. Human three-dimensional fibroblast cultures express angiogenic activity. J Cell Physiol 2000 Apr; 183 (1): 74-82
162. Kellar RS, Landeen LK, Shepherd BR, et al. Scaffold-based three-dimensional human fibroblast culture provides a structural matrix that supports angiogenesis in infarcted heart tissue. Circulation 2001 Oct 23; 104 (17): 2063-8
163. Kellar RS, Shepherd BR, Larson DF, et al. Cardiac patch constructed from human fibroblasts attenuates reduction in cardiac function after acute infarct. Tissue Eng 2005 Nov-Dec; 11 (11-12): 1678-87
164. Gentzkow GD, Iwasaki SD, Hershon KS, et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996 Apr; 19 (4): 350-4
165. Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artif Organs 1997 Nov; 21 (11): 1203-10